<i>In vitro</i> small molecule screening to inform novel candidates for use in fluconazole combination therapy <i>in vivo</i> against <i>Coccidioides</i>.

ABSTRACT: Identifying improved treatments for severe and refractory coccidioidomycosis (Valley fever) is needed. This endemic fungal disease is common in North and South America, and cases have increased substantially over the last 30 years. The current standard of care, oral daily fluconazole, often fails to completely eradicate Coccidioides infection; however, the high cost of identifying new compounds effective in treating Valley fever is a barrier to improving treatment. Therefore, repurposing existing pharmaceutical agents in combination with fluconazole therapy is an attractive option. We screened the Library of Pharmacologically Active Compounds (LOPAC) small molecule library for compounds that inhibited fungal growth in vitro and determined IC₅₀ values for a subset o

SUBMITTER: Mead HL 

PROVIDER: S-EPMC11448266 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature